UroGen Pharma (URGN) Capital Expenditures (QoQ) (2017 - 2026)
UroGen Pharma (URGN) Capital Expenditures (QoQ) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | UroGen Pharma | 2.13 Bn | 1.99 Bn | 46.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 245.93% |
| Dec 31, 2025 | -126.82% |
| Sep 30, 2025 | 1,285.58% |
| Jun 30, 2025 | 297.25% |
| Mar 31, 2025 | -199.54% |
| Dec 31, 2024 | 172.28% |
| Sep 30, 2024 | 28.71% |
| Jun 30, 2024 | 54.79% |
| Mar 31, 2024 | -7,733.33% |
| Dec 31, 2023 | 98.44% |
| Sep 30, 2023 | -122.97% |
| Jun 30, 2023 | -181.71% |
| Mar 31, 2023 | 56.51% |
| Dec 31, 2022 | -51.62% |
| Sep 30, 2022 | 102.18% |
| Jun 30, 2022 | 62.72% |
| Mar 31, 2022 | 130.56% |
| Dec 31, 2021 | -201.10% |
| Sep 30, 2021 | -25.98% |
| Jun 30, 2021 | 157.49% |